Search Results

0 results for 'Janssen Pharmaceutical'

You can use to get even better search results
April 03, 2024 | The Legal Intelligencer

'How Can It Be Enough?': Thousands Have Agreed to the Risperdal Settlement. A Few Holdouts Remain

According to attorneys leading the litigation, more than 5,600 have agreed to the settlement, which is about 94% of the potential 6,000 claims for the bulk settlement. The lawyers said 99.9% of claimants have chosen to accept their settlement offers.
12 minute read
April 02, 2024 | The Legal Intelligencer

Up to $1.1 Billion: Inside the Settlement Resolving Most of Philadelphia's Risperdal Cases

According to settlement records, the settlement's group expenses were $33 million, with additional costs expected to be incurred.
7 minute read
April 02, 2024 | New Jersey Law Journal

Up to $1.1 Billion: Inside the Settlement Resolving Thousands of Risperdal Cases Against J&J Subsidiary

According to settlement records, the settlement's group expenses were $33 million, with additional costs expected to be incurred.
7 minute read
March 20, 2024 | New Jersey Law Journal

Blank Rome Files Trade Secrets Suit Against Former J&J Employee for Departing to Pfizer

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign up today and be among the first to know about new suits in your region, practice area or client sector.
3 minute read
March 11, 2024 | The Legal Intelligencer

Phila. Mass Tort Over Janssen Bladder Drug Winds Down Without Bellwether Trial

The first trial in the mass tort had been scheduled to begin Monday, but most of the program's cases were resolved through confidential settlements in the last six months, according to Kline & Specter partner Tobi Millrood, who serves as plaintiffs liaison counsel in the matter.
3 minute read
January 19, 2024 | New Jersey Law Journal

Big Law Squares Off in Battle Over Prescription Drug Prices

Courts have consistently rejected challenges under the Takings Clause to federal health care programs that seek to limit costs, according to an amicus curiae brief by a panel of nine nationally recognized experts in Medicare and medical finance.
5 minute read
Janssen Prods., L.P. v. Evenus Pharm. Labs. Inc.
Publication Date: 2023-11-06
Practice Area: Intellectual Property
Industry: Pharmaceuticals
Court: U.S. Court of Appeals for the Third Circuit
Judge: Justice Smith
Attorneys:
For plaintiff: Roy T. Englert, Jr., Shikha Garg (Kramer Levin Naftalis & Frankel); Peter C. Harvey (Patterson Belknap Webb & Tyler); Lisa Kobialka (Kramer Levin Naftalis & Frankel); Irena Royzman, Daniel I. Sugarman, Christine Willgoos (Kramer Levin Naftalis & Frankel)
For defendant: Arnold B. Calmann, Katherine A. Escanlar (Saiber); Clifton S. Elgarten, Ali H. K. Tehrani (Crowell & Moring); James K. Stronski (Crowell & Moring)
Case number: 22-2426

Appeal Dismissed Where Denial of DTSA Seizure Request Was Not an Immediately Appealable Order

November 02, 2023 | The Recorder

Johnson & Johnson, IBM Targeted in Class Action Over Health Care Data Breach

The complaint was first surfaced by Law.com Radar.
2 minute read
October 02, 2023 | New Jersey Law Journal

New Name or Not, Johnson & Johnson Can't Escape Talc Damages

"In other words, regardless of Johnson & Johnson trying to bankrupt their subsidiary, the company that has the assets is ultimately responsible under New Jersey law," Christopher Placitella, who represents plaintiffs in the asbestos litigation, said.
4 minute read

TRENDING STORIES

    Resources

    • Practical Guidance Journal: Protecting Work Product in a Generative AI World

      Brought to you by LexisNexis®

      Download Now

    • Countdown to Compliance: SEC Private Fund Reforms

      Brought to you by Ontra

      Download Now

    • The Future of AI in Law

      Brought to you by Filevine

      Download Now

    • The Power of Trust Accounting for Law Firm Success

      Brought to you by Juris Ledger

      Download Now